This study had several limitations. The most important restrictions were as follows: 1) the cross-
Conditions
Interventions
Doses were scaled from small doses and the starting dose was 25 mg until maximum of 300 mg/day pills. The daily usage was divided to two dosages of morning and afternoon. The urine test band was rando
Creatinine and PH and threshold of 300 ng/ml was used for the urine analysis. All the topiramate capsules together with monohydrate lactose powder were provided less than sixty days before usage. Lact
Experimental Drug
Topiramate (TPM)
Sponsors
non
Eligibility
Sex/Gender
Male
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria were: 1) young Male (18-55 year) patients; 2) diagnostic criteria for cocaine and opioid dependence according to DSM-IV and 3) eligible for methadone maintenance.
Exclusion criteria
Exclusion criteria: Exclusion criteria were: 1) report of positive urine test during the remedial period; 2) Hypersensitivity to TPM; 3) nephrolithiasis or renal impairment, kidney failure history, serious mental disorde
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| on a primary outcome, Topiramate was not better than placebo in reducing cocaine use 12-week generalized estimating equations (GEE) ,Topiramate was not better than placebo in reducing cocaine use 12-week generalized estimating equations (GEE) | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome was showed Topiramate was better than placebo in reducing cocaine craving 12-week generalized estimating equations (GEE) ,The mean [95% confidence interval (CI)] scores of cocaine craving was 11.42 (7.74–16.10) with exp 12-week generalized estimating equations (GEE) | — |
Contacts
Public Contactbijan pirnia
phD student
Outcome results
None listed